Skip to main content
SCYX
NASDAQ Life Sciences

SCYNEXIS Files Definitive Proxy for Reverse Stock Split to Maintain Nasdaq Listing

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
8
Price
$1.01
Mkt Cap
$44.664M
52W Low
$0.565
52W High
$1.31
Market data snapshot near publication time

summarizeSummary

SCYNEXIS has filed its definitive proxy statement for a special meeting on May 19, 2026, seeking shareholder approval for a reverse stock split (1-for-5 to 1-for-10) to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting.


check_boxKey Events

  • Shareholder Vote Scheduled

    A special meeting of stockholders is scheduled for May 19, 2026, to vote on the proposed reverse stock split.

  • Reverse Stock Split Proposed

    The Board seeks approval for an amendment to implement a reverse stock split at a ratio ranging from 1-for-5 to 1-for-10, at its discretion.

  • Nasdaq Compliance Critical

    The primary purpose of the reverse stock split is to regain compliance with Nasdaq's $1.00 minimum bid price requirement by June 15, 2026, to prevent delisting.

  • Authorized Shares to Decrease Proportionately

    The proposal includes a proportionate reduction in the number of authorized common shares based on the reverse stock split ratio.


auto_awesomeAnalysis

This definitive proxy statement confirms SCYNEXIS's plan to execute a reverse stock split, a critical step to maintain its listing on The Nasdaq Capital Market. While reverse splits are often viewed negatively as they don't change fundamental value and can sometimes lead to further price declines, this action is necessary to avoid delisting, which would severely impact liquidity and access to capital. The proposal also includes a proportionate reduction in authorized shares, which could mitigate future dilution compared to maintaining a high authorized share count post-split. Investors should monitor the outcome of the May 19th special meeting and the subsequent impact on the stock's trading price and Nasdaq compliance.

At the time of this filing, SCYX was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.7M. The 52-week trading range was $0.57 to $1.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SCYX - Latest Insights

SCYX
Apr 27, 2026, 4:18 PM EDT
Filing Type: DEF 14A
Importance Score:
8
SCYX
Apr 20, 2026, 5:24 PM EDT
Filing Type: PRE 14A
Importance Score:
9
SCYX
Apr 17, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
8
SCYX
Apr 02, 2026, 8:01 AM EDT
Filing Type: 4
Importance Score:
8
SCYX
Mar 31, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
9
SCYX
Mar 31, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
SCYX
Mar 31, 2026, 6:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
SCYX
Mar 04, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
8
SCYX
Mar 04, 2026, 4:01 PM EST
Filing Type: 10-K
Importance Score:
9